home / stock / agnpf / agnpf news

AGNPF News and Press, Algernon Pharmaceuticals Inc - Class A From 09/08/22

Stock Information
Company Name: Algernon Pharmaceuticals Inc - Class A
Stock Symbol: AGNPF
Market: OTC
Website: algernonpharmaceuticals.com
Menu
AGNPF AGNPF Quote AGNPF Short AGNPF News AGNPF Articles AGNPF Message Board
Get AGNPF Alerts

News, Short Squeeze, Breakout and More Instantly...
AGNPF - Microdose Announces Algernon Pharmaceuticals as Wonderland's Headline Sponsor

Miami, Florida--(Newsfile Corp. - September 8, 2022) - Microdose Psychedelic Insights , the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals  (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland...
AGNPF - Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

VANCOUVER, British Columbia, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that ...

AGNPF - Algernon posts full Phase 2 data set for lung disease candidate

Canadian biopharma company Algernon Pharmaceuticals Inc. ( OTCQB:AGNPF ) announced the complete data set from its Phase 2a study for lead candidate NP-120 (“Ifenprodil”) in idiopathic pulmonary fibrosis (“IPF”) and chronic cough. Announcing topline ...

AGNPF - Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to report po...
AGNPF - Algernon Pharmaceuticals' Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that its largest shareholder, AlphaNorth Asset Management (“AlphaN...

AGNPF - Algernon Pharmaceuticals Announces Closing of Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”...

AGNPF - Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce it has...
AGNPF - Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce additi...

AGNPF - Algernon lung disease drug hits one goal, misses out on another in mid-stage study

Algernon Pharmaceuticals' ( OTCQB:AGNPF ) drug NP-120 (Ifenprodil) met one main goal but missed out on another in a phase 2 proof of concept study to treat idiopathic pulmonary fibrosis (IPF) and chronic cough. IPF is a condition in which the lungs become scarred and breathing b...

AGNPF - Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce positi...
Previous 10 Next 10